Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development
- 22 February 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 64 (5), 2419-2435
- https://doi.org/10.1021/acs.jmedchem.0c01487
Abstract
Bromodomain and extraterminal (BET) proteins bind acetylated lysine residues in histones and nonhistone proteins via tandem bromodomains and regulate chromatin dynamics, cellular processes, and disease procession. Thus targeting BET proteins is a promising strategy for treating various diseases, especially malignant tumors and chronic inflammation. Many pan-BET small-molecule inhibitors have been described, and some of them are in clinical evaluation. Nevertheless, the limited clinical efficacy of the current BET inhibitors is also evident and has inspired the development of new technologies to improve their clinical outcomes and minimize unwanted side effects. In this Review, we summarize the latest protein characteristics and biological functions of BRD4 as an example of BET proteins, analyze the clinical development status and preclinical resistance mechanisms, and discuss recent advances in BRD4-selective inhibitors, dual-target BET inhibitors, proteolysis targeting chimera degraders, and protein–protein interaction inhibitors.Keywords
Funding Information
- China Postdoctoral Science Foundation (2020M673268)
- Department of Science and Technology of Sichuan Province (20YYJC3921)
- Cancer Prevention and Research Institute of Texas (RP180349, RP190077)
- National Natural Science Foundation of China (81673290, 81874290, 81903502, 81922064)
- National Institutes of Health (1RO1CA251698-01)
This publication has 133 references indexed in Scilit:
- Small-Molecule Inhibition of BRDT for Male ContraceptionCell, 2012
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain FamilyCell, 2012
- Peptoid ligands that bind selectively to phosphoproteinsBioorganic & Medicinal Chemistry Letters, 2011
- Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genesProceedings of the National Academy of Sciences of the United States of America, 2011
- Brd4 engagement from chromatin targeting to transcriptional regulation: selective contact with acetylated histone H3 and H4F1000 Biology Reports, 2009
- Brd4 Coactivates Transcriptional Activation of NF-κB via Specific Binding to Acetylated RelAMolecular and Cellular Biology, 2009
- The Double Bromodomain Proteins Brd2 and Brd3 Couple Histone Acetylation to TranscriptionMolecular Cell, 2008
- Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcriptionProceedings of the National Academy of Sciences of the United States of America, 2007
- Regulation of P-TEFb Elongation Complex Activity by CDK9 AcetylationMolecular and Cellular Biology, 2007
- Identification of Transcription Complexes that Contain the Double Bromodomain Protein Brd2 and Chromatin Remodeling MachinesJournal of Proteome Research, 2006